OncoMatch/Leukemia — Acute Myeloid (AML)/IDH1
Leukemia — Acute Myeloid (AML)IDH1 Clinical Trials
IDH1 mutations occur in 7–10% of AML and produce the oncometabolite 2-hydroxyglutarate (2-HG), driving epigenetic dysregulation and differentiation block. Ivosidenib is FDA-approved as monotherapy for relapsed/refractory IDH1-mutant AML and in combination with azacitidine for newly diagnosed patients ineligible for intensive chemotherapy. Trials investigate ivosidenib combinations with venetoclax, HMA/venetoclax triplets, and 2-HG as a pharmacodynamic biomarker.
Top recruiting IDH1 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier Affaires Médicales
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital